Tools
Neuronal Brain Tumors
Introduction
Neuronal brain tumors are an uncommon group of central nervous system tumors that arise from cells with neuronal differentiation. These tumors may be purely neuronal in origin or have mixed neuronal and glial components, which comprise a subset of glioneuronal tumors.[1] The 2021 World Health Organization (WHO) classification of central nervous system (CNS) tumors includes 14 distinct tumors within this classification.
The purely neuronal group includes gangliocytoma, multinodular and vacuolating neuronal tumor (MVNT), dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease), central neurocytoma, extraventricular neurocytoma, and cerebellar liponeurocytoma. The mixed glioneuronal group includes ganglioglioma, desmoplastic infantile ganglioglioma/desmoplastic infantile astrocytoma (DIG/DIA), dysembryoplastic neuroepithelial tumor (DNET), diffuse glioneuronal tumor with oligodendroglioma-like features and nuclear clusters (DGONC), papillary glioneuronal tumor (PGT), rosette-forming glioneuronal tumor (RGNT), myxoid glioneuronal tumor (MGT), and diffuse leptomeningeal glioneuronal tumor (DLGNT). MVNT, DGONC, and MGT are newly classified entities in the WHO CNS tumor classification schema.
Although there are some exceptions, these tumors are mostly low-grade with minimal risk for an aggressive clinical course. They are most commonly present with seizures, although other symptoms of space-occupying intracranial lesions, such as headache, vomiting, papilledema, cerebellar dysfunction, and focal neurological deficit, have also been described.[2][3] Many of these tumors are commonly found in the temporal lobe, which helps explain their predilection for causing seizures.[4] However, these tumors can be found throughout the supratentorial and infratentorial spaces.
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
There is no specific etiology or risk factor related to the development of this diverse group of tumors. However, the current emphasis on molecular characterization of brain tumors provides new insight into the genetic aberrations that underlie their tumorigenesis. Specifically, 2 main molecular subgroups may involve mutations within different cellular regulation pathways. The first subgroup demonstrates mutation in the mitogen-activated protein kinase (MAPK) pathway, which is involved in cellular growth. Specifically, alterations to the proto-oncogene BRAF in the form of BRAF fusion and single nucleotide missense mutations are commonly found in these tumors, with the highest incidence in gangliocytoma and ganglioglioma, with 25% demonstrating fusion mutation and 13-56% demonstrating single nucleotide missense mutation.[5] They have also been described in DLGNT and isolated cases of MVNT.[6][7]
These are gain-of-function mutations that lead to unregulated cell growth. The second group demonstrates mutation in fibroblast growth factor (FGFR) genes, mostly FGFR-1, upstream from the MAPK pathway.[8][9][10] This appears to be especially common in DNETs but has also been identified in neurocytoma and RGNT.[11][12] Interestingly, these molecular subgroups may help distinguish between tumor types for the glioneuronal group. The BRAF mutation group tends to have a glial component similar to astrocytes, while the FGFR group tends to have a glial component similar to oligodendroglia.
MGTs are newly recognized lesions within the neuronal and glioneuronal tumor groups. They are similar to DNET but have a predilection for location in the septum pellucidum. They are associated with a mutation in the platelet-derived growth factor receptor (PDGFR) gene instead of FGFR.[13][14] This tumor was often previously described as “intraventricular DNET” or “DNET-like neoplasm of the septum pellucidum.”
PGNTs also demonstrate unique genetic aberrations among the neuronal and glioneuronal tumor groups. These often harbor a fusion aberration between solute carrier family 44 choline transporter 1 (SLC44A1) and protein kinase C alpha (PRKCA), creating SLC44A1-PRKCA.[15] Notably, PRKCA is involved in the MAPK signaling pathway.[16] However, these tumors do not have the BRAF mutations that other neuronal and glioneuronal tumors with mutations in the MAPK pathway are found to have.
Dysplastic cerebellar gangliocytoma, also referred to as Lhermitte-Duclos disease, represents a special case within this group of tumors because it is associated with Cowden syndrome, which is also referred to as phosphatase and tensin homolog (PTEN) hamartoma tumor syndrome.[17] PTEN contributes to the mammalian target of the rapamycin (mTOR) pathway, which helps regulate the cell cycle. Wild-type PTEN downregulates the pathway, which reduces proliferation. Mutations in PTEN can lead to unregulated mTOR signaling, which results in tumorigenesis. Common findings in Cowden syndrome include macrocephaly, developmental delay, hemangiomas or other vascular lesions, thyroid hamartomas, breast hamartomas, ganglioneuromas of the kidney, uterine fibroids, various skin lesions including lipomas and keratoses, and dysplastic cerebellar gangliocytoma.
It is important to note that not all tumor samples are found to have the molecular aberrations noted above and that these do not represent all aberrations that have been associated with neuronal and glioneuronal tumors. Other mutations upstream from the signaling pathways noted above may contribute to their development. However, the rare nature of this group of tumors makes their molecular characterization somewhat difficult, with most information gleaned from case reports and small case series. Ongoing efforts are working towards a better understanding of the genetic alterations contributing to their development.
Epidemiology
This is a rare group of brain tumors totaling approximately 0.5 to 2% of all primary CNS tumors.[4] Ganglioglioma and DNET make up the majority of the group. At the same time, descriptions of many newly classified lesions, such as MVNT, DGONC, MGT, and others, are limited to case reports and small case series, likely representing a small portion of all primary CNS tumors. These are primarily tumors of childhood and young adulthood. A diagnosis greater than 30 years old is a rare clinical scenario.
Pathophysiology
Neuronal and glioneuronal tumors are primary CNS tumors arising, at least partially, from mutations in cellular growth pathways, as noted earlier. Due to their rarity, the precise molecular characterization of many of these tumors remains difficult, but ongoing efforts continue to uncover genetic aberrations leading to their development.
Tumor location plays a major role in the pathophysiology of most of these lesions as they are typically WHO 1. Central neurocytoma, extraventricular neurocytoma, and cerebellar liponeurocytoma are WHO grade 2 lesions. The anaplastic form of ganglioglioma represents the group's only WHO grade 3 lesions. Due to their rarity, some newly described tumors, such as DLGNT and MGT, do not yet have a classification. As noted, these tumors can occur anywhere in the supratentorial or infratentorial space, although certain tumors have a predilection for a specific location. For example, dysplastic cerebellar gangliocytoma occurs in the cerebellum, similar to Lhermitte-Duclos disease, in the setting of Cowden syndrome.[17]
However, the most common tumor location appears to be in the temporal lobe, partly because ganglioglioma and DNET are the most common tumor types within this group and have a predilection for this location. These tumors are also found in extra-temporal locations.[18] Location in the temporal lobe and other epileptogenic regions contributes to the development of seizures, which is the most common presenting symptom of this group of tumors.[9][10] Due to this, they are often referred to as long-term epilepsy-associated tumors (LEATs), and their seizures are often refractory to maximal medical therapy.[6][18][19]
The propensity for these tumors to cause seizures may not only be related to their location since intra-tumoral EEG recordings have demonstrated intrinsic epileptogenic activity in both DNET and ganglioglioma, likely related to their abnormal neuronal cells and structure.[19][20][21][22] Additionally, some studies suggest an upregulation of glutamate receptors (GluR) and downregulation of gamma-aminobutyric acid receptors (GABA-R), which help to create a hyper-excitable state within the tumor.[19][23][24][25][26]
Other symptoms are also related to location. Headache, nausea, vomiting, papilledema, hydrocephalus, cerebellar dysfunction, and focal neurological deficit have also been described. Headache, vomiting, and papilledema are signs of elevated intracranial pressure, which is expected with space-occupying lesions. Since many of these lesions are slow-growing, they may reach large sizes before clinical recognition, with these signs and symptoms being the initial presenting factor that leads to tumor recognition.
Hydrocephalus is mainly secondary to intraventricular or posterior fossa lesions, as tumors in these locations can disrupt the normal cerebrospinal fluid (CSF) outflow pathways. This is usually obstructive-type hydrocephalus, which may be acute if there is a sudden block of normal CSF outflow pathways, as in rare cases of central neurocytoma.[27] Due to its location, Cerebellar dysfunction is common with dysplastic cerebellar gangliocytoma, and other focal neurological deficits are related to individual tumor location within the cerebrum.
Histopathology
The histological features of neuronal and glioneuronal tumors are heterogeneous. All neuronal and glioneuronal tumors should demonstrate positivity for immunohistochemical staining with neuronal cell markers, such as synaptophysin or neuron-specific enolase (NSE).[28][29] However, only the glioneuronal subgroup of tumors should demonstrate positivity for glial differentiation markers in addition to neuronal marker positivity, which is classically seen with glial fibrillary acidic protein (GFAP) positivity. The Ki-67 marker of cellular proliferation is typically low, although higher proliferation rates may be seen for higher-grade tumors such as anaplastic astrocytoma. Cells with oligodendroglia-type cells often demonstrate Olig2 positivity. The major histopathological features of each type of tumor are summarized in Table 1, although details of the immunohistopathological profile of each tumor are not exhaustive in this report.
Table 1: Histological features of individual neuronal and glioneuronal tumors.[30][31]
| Tumor | Features | Special Characteristics |
|
Gangliocytoma |
|
|
|
MVNT |
|
|
|
Dysplastic cerebellar gangliocytoma |
|
|
|
Central neurocytoma |
|
|
|
Extraventricular neurocytoma |
|
|
|
Cerebellar liponeurocytoma |
|
|
|
Ganglioglioma |
|
|
|
DIG/DIA |
|
|
|
DNET |
|
|
|
DGONC |
|
|
|
PGNT |
|
|
|
RGNT |
|
|
|
MGT |
|
|
|
DLGNT
|
|
|
History and Physical
The findings for an individual patient with a neuronal or glioneuronal brain tumor are variable. A detailed history of the patient’s seizure history should be obtained, including a detailed description of the seizure, whether the patient has previously been evaluated for seizures, and whether there are any family members with a history of seizures. The presence, duration, and severity of other signs and symptoms such as headache, nausea, vomiting, balance difficulties, focal weakness or sensory changes, changes to eyesight, or others should also be obtained. A detailed history of current and previous diagnoses should also be obtained, including current and previous prescription and non-prescription medication.
Next, the practitioner should perform a detailed physical exam focusing on the neurological system. When possible, the examiner must evaluate for mental status changes, visual field deficits, cranial nerve dysfunction, focal neurological deficits, motor or sensory disruptions, cerebellar dysfunction, and papilledema.
For most patients, the physical examination is within normal limits. Rarely, patients may present with acute alteration in mental status and obtundation signifying acute hydrocephalus secondary to CSF outflow obstruction, which may occur with intraventricular tumors such as central neurocytoma or with seizure.
Patients with posterior fossa lesions often demonstrate cerebellar symptoms on examination, such as ataxia, unsteady gait, and a positive Romberg sign, among others. Other focal neurological deficits may include sensory changes or focal weakness, but again, these would be rare due to the indolent nature of most of these lesions and the brain's ability to compensate. Post-ictal patients and those presenting with acute status change secondary to acute hydrocephalus require frequent serial neurological evaluation.
Evaluation
The initial evaluation of a patient suspected of a neuronal or glioneuronal brain tumor requires a detailed history and physical examination, as noted above. Importantly, although rare, patients with acute neurological status changes need an emergent evaluation of the airway status, breathing/oxygenation, and circulatory system (ABCs). This scenario may occur in patients with acute hydrocephalus and may also be true for patients presenting with generalized tonic-clonic or subclinical seizure activity. There should be a low threshold for intubation and resuscitation when a compromise is noted on the initial assessment of the ABCs. However, most patients present with focal partial seizures and signs of increased intracranial pressure, such as headaches.
CT
Patients presenting with acute deficit should first undergo a head CT without contrast after clinical stabilization due to the rapidity of the test and its ability to demonstrate common causes of acute status change, such as hemorrhage. Its most useful feature is demonstrating hydrocephalus, which may require emergent surgical action.[27] Depending on the tumor location, CT findings consistent with hydrocephalus may include enlargement of the temporal horns, triventricular or tetraventricular enlargement, and hypodensities around the frontal horns suggesting transependymal flow of CSF.[32][33]
Other CT findings include hyperdensity within the ventricular system for intraventricular lesions such as central neurocytoma and hypo- or iso-density in the brain parenchyma representing intraparenchymal lesions.[34][35] The head CT may also show calcification, but this is likely present in less than half of all neuronal and glioneuronal brain tumors. Approximately 10% of DNET and 35 to 50% of ganglioglioma demonstrate calcifications, while other primary CNS lesions like oligodendroglioma demonstrate calcification in up to 90% of lesions.[36]
MRI
MRI is the imaging test of choice for evaluating this group of brain tumors.[36][37] Sequences should include T1—and T2-weighted images with and without gadolinium contrast. Fluid-attenuated inversion recovery (FLAIR) imaging for tumor characterization and edema, susceptibility-weighted imaging (SWI) for hemorrhage and calcification, diffusion-weighted imaging (DWI) for an assessment of cellularity, and perfusion-weighted imaging (PWI) for an assessment of angiogenesis should be included as part of a standard brain tumor imaging protocol when a primary CNS tumor is suspected.
Other advanced MRI techniques, such as MR spectroscopy (MRS), diffusion tensor imaging (DTI), and functional MRI (fMRI), can also be useful. Table 2 demonstrates the most common MRI characteristics for each tumor. Due to the rare nature of many of these lesions, complete imaging characteristics are still being defined. Additionally, many of these lesions have heterogeneous imaging characteristics, and individual tumors may not demonstrate the standard features noted here.
Table 2: MRI characteristics for individual neuronal and glioneuronal brain tumors.[4][17][37][38][39]
| Tumor | T1 | T2 | FLAIR | Contrast enhancement | DWI | PWI | SWI | Special features |
|
Gangliocytoma |
Hypointense | Hyperintense, except cystic portions, are hypointense | Minimal to no edema | Usually present | None | NA | NA | NA |
|
MVNT |
Hypointense nodules | Hyperintense nodules | Hyperintense nodules; Minimal or no edema | None | None | Mild decrease in perfusion compared with the surrounding parenchyma | NA | Well-defined nodules |
|
Dysplastic cerebellar gangliocytoma |
Hypointense | Hyperintense “tiger-stripe” or “tigroid” appearance | Hyperintense tumor; no surrounding edema | None to minimal | None | Mild increase in perfusion | NA |
The “Tiger-stripe” appearance corresponds to the widening of the cerebellar folia. These are typically unilateral tumors. MRS has a prominent lactate peak and a reduced choline peak. |
|
Central neurocytoma |
Isointense | Hyperintense “soap-bubble” appearance | Hyperintense solid component, Hypointense cystic component; no edema | Present in the solid component | Frequent diffusion restriction in the solid component | Mild increase in perfusion | NA | Usually attached to the septum pellucidum, calcifications are common. Glycine and choline peaks are found on MRS; they may cause obstructive hydrocephalus. |
|
Extraventricular neurocytoma |
Isointense | Hyperintense | Hyperintense solid component, Hypointense cystic component; usually significant edema | Heterogenous | Frequent diffusion restriction in the solid component | Occasional increase in perfusion | Hemorrhage found in 20-45% | NA |
|
Cerebellar liponeurocytoma |
Hypointense | Hyperintense | Hyperintense lesion; usually no surrounding edema | Heterogenous | Frequent | NA | NA | It may also be intraventricular |
|
Ganglioglioma |
Hypo- or iso-intense | Hyperintense | Minimal edema for low-grade tumors; significant edema for anaplastic WHO 3 variant | The mural nodule enhances when it is present; irregular or heterogenous enhancement with solid masses. | None, even with the anaplastic variant. | Mild increase in perfusion, especially the anaplastic variant | NA | Calcification is seen in about 50%; present as a solid mass or a mural nodule with a cyst, they may infiltrate white matter tracts. |
|
DIG/DIA |
Isointense solid component; hypointense cystic component | Heterogenous solid component; hypointense cystic component | Mild edema | The solid portion strongly enhances, especially in DIA | None | NA | NA | Often involves the superficial cortex and leptomeninges, appearing attached to the dura. |
|
DNET |
Hypointense | Hyperintense | Hyperintense solid component; hypointense cystic component; no edema | Uncommon; may be nodular or heterogenous | None | Mild decrease compared to surrounding parenchyma | NA | A well-demarcated lesion with cystic regions; FLAIR “ring sign” may be seen; displaces white matter tracts. |
|
DGONC |
Hypointense | Hyperintense | Hyperintense; no edema | Minimal to no enhancement | NA | NA | NA | Calcification is possible |
|
PGNT |
Hypo- or iso-intense solid component; hypointense cystic component | Hyperintense solid component | Hyperintense solid component | Intense enhancement in the solid portion; possible ring enhancement around cysts | NA | NA | Hemorrhage is seen in 10% | Solid and cystic fluids are usually mixed, calcification is often present, and prominent septation in the cyst is a distinctive feature. |
|
RGNT |
Hypointense solid and cystic components | Hyperintense | No edema | A variable amount of peripheral heterogeneous enhancement | None | NA | Occasional hemorrhage | MRS shows an elevated choline peak and a reduced N-acetyl aspartate (NAA) peak, which may be entirely solid, cystic, or mixed. |
|
MGT |
Hypointense | Hyperintense | Hyperintense; No edema | None | None | NA | Possible hemorrhage | Usually found at the septum pellucidum, it may cause obstructive hydrocephalus and may disseminate in the ventricular system. |
|
DLGNT |
NA | Hyperintense | NA | Diffuse leptomeningeal enhancement | NA | NA | NA | It occurs predominantly around the basal cisterns, extends throughout the CNS, and may cause obstructive hydrocephalus; subpial lesions are usually present. |
Most of the tumors within this group are primary intracranial lesions without dissemination or occurrence in other compartments within the CNS. However, patients with DLGNT, in particular, should undergo MRI with and without contrast of the entire neuroaxis due to its proclivity for dissemination throughout the neuroaxis. Consideration of imaging the spinal axis should also be given for other patients with focal neurological deficits or signs of myelopathy that cannot be explained by their intracranial lesion alone.
EEG
An important consideration for this group of brain tumors is electroencephalography (EEG) since they commonly present with seizures. Spot EEG may be useful in some cases, but continuous video EEG monitoring allows for better characterization of seizure semiology and assists with the localization of an epileptogenic focus. Invasive EEG monitoring with either subdural strip electrodes or depth electrodes can also be considered in patients with seizures that cannot be localized to the region of the tumor with noninvasive recording techniques. The specific histologic characteristics of an individual tumor may affect EEG characteristics. Tumors with mostly neuronal histology often demonstrate continuous spiking.[40] However, there are limited data regarding specific EEG characteristics for these tumors.
WADA Testing
Many LEATs are in locations where surgical resection may compromise language function. WADA testing is typically employed in these patients before resection to identify language dominance and assist with surgical planning.[41] fMRI has also been used for this purpose, but it may not be as accurate as WADA testing, which remains the gold standard for determining language dominance.[42]
Interprofessional Discussion
LEAT patients should be discussed in interprofessional epilepsy conferences involving neurosurgeons, epilepsy neurologists, neuroradiologists, and neuropathologists to make appropriate diagnostic and treatment plans for these often-complicated patients. Furthermore, these patients and others with tumors that are identified for another reason should be discussed at an interprofessional tumor board conference consisting of neurosurgeons, neurologists, neuroradiologists, neuropathologists, radiation oncologists, and medical oncologists to assist with appropriate diagnostic and treatment planning.
Treatment / Management
Observation
Asymptomatic or minimally symptomatic lesions identified on imaging for another reason can be reasonably followed with serial examination and neurological imaging due to the primarily low-grade nature of this group of tumors. Changes to the radiological characteristics of the tumor or the development of new neurological symptoms should prompt discussion at interprofessional conferences to consider intervention.
Medical Treatment for Seizures
Medical treatment for this group of tumors chiefly encompasses the use of anti-epileptic medications for LEATs. The specific agents used are variable, and typically, various agents are trialed. However, these tumors are often refractory to maximal medical therapy and typically require surgical intervention.[19](B3)
Surgical Treatment
Surgical resection is the treatment of choice for symptomatic neuronal and glioneuronal tumors.[43] Patients who present with acute obstructive hydrocephalus require emergent surgery to prevent permanent neurological injury and death. However, that clinical scenario is unusual for this group, and most others can typically be scheduled on an outpatient basis after the decision for the need for surgical intervention has been reached in interprofessional conferences. The specifics of the intervention are highly dependent on the tumor's location. This typically involves a craniotomy with the goal of gross total tumor resection. However, some data suggest that a small residual tumor may still result in sufficient resection in the case of LEATs.[43]
Gross total resection for higher-grade lesions appears to be more important. A higher extent of resection (EOR) improves survival in patients with anaplastic ganglioglioma, similar to data from other high-grade CNS lesions such as glioblastoma.[44][45] The increasing EOR in central neurocytoma has also demonstrated a survival benefit.[46] Intraventricular lesions within this group have historically been treated with standard craniotomy and tumor resection, but modern minimally invasive surgical techniques using tubular retractor systems are beginning to emerge.[47][48](B2)
These may help reduce some of the morbidity related to intraventricular surgery for large tumors. Laser interstitial thermal therapy (LITT) is another emerging minimally invasive surgical strategy for intracranial lesions that has been applied to brain tumors and epilepsy surgery.[49] This technique utilizes light energy to cause a thermal reaction within the target tissue, resulting in lesionectomy. Its application to neuronal and glioneuronal tumors, in particular, is limited at this time. However, it may emerge as an alternative to formal surgical resection for tumors in deep-seated and eloquent tissues.
Radiation Therapy
The role of radiation is somewhat limited for this group of tumors since most are WHO grade I. However, higher-grade lesions including anaplastic ganglioglioma, liponeurocytoma, and some central/extraventricular neurocytoma may require adjuvant radiation therapy. Radiation is most commonly employed for anaplastic ganglioglioma, although it is not employed in all cases.[50][51] (B2)
In cases of gross total resection for anaplastic ganglioglioma, adjuvant radiation therapy alone may be considered, but clinicians should consider adjuvant chemoradiation therapy in cases of subtotal resection.[52] The use of adjuvant radiation therapy for central and extraventricular neurocytoma is also common and appears to improve survival, especially in cases of subtotal resection or tumor recurrence.[53][54][55](B2)
Liponeurocytoma may also be treated with postoperative radiation. In case reports and small case series, patients who underwent subtotal resection or recurrent liponeurocytoma have been successfully treated with adjuvant radiotherapy.[56][57][58] Further study, ideally with randomized controlled clinical trials, is necessary to define the exact role of radiation therapy for this group of tumors as a whole, but this may be difficult due to the rare nature of many of these tumors.(A1)
Chemo- and Immunotherapy
Chemo- and immuno-therapies are typically reserved for grade 2 and 3 tumors in a fashion similar to radiation therapy. Immunotherapies targeting BRAF are emerging as adjuvant therapy for use in anaplastic ganglioglioma.[44][59][60] Examples of BRAF inhibitors include vemurafenib, dabrafenib, and encorafenib. The use of chemotherapy in central neurocytoma is variable and typically reserved for patients with recurrent tumors.[61](B3)
Agents such as vincristine, cisplatin, etoposide, carboplatin, cyclophosphamide, and lomustine have all been documented in case reports and small cases series for use in central neurocytoma.[62] However, temozolomide, an alkylating agent available in oral and intravenous forms that is a common agent for central nervous system malignancies, has recently been favored. Treatment using chemo-or immuno-therapies for liponeurocytoma is not well documented.(B3)
Differential Diagnosis
The differential diagnosis for neuronal and glioneuronal brain tumors is broad due to their heterogeneous nature. Other primary central nervous system tumors, especially low-grade ones, may appear similar.
- Diffuse astrocytoma
- Pilomyxoid astrocytoma
- Pleomorphic xanthoastrocytoma
- Pilocytic astrocytoma
- Oligodendroglioma
- Lymphoma
- Ependymoma
- Intraventricular tumors for central neurocytoma: Subependymal giant cell astrocytoma (SEGA); meningioma; choroid plexus papilloma or carcinoma; metastasis
- Dural-based tumors for DIG/DIA: Meningioma; dural-based metastases
- Cerebritis
Prognosis
Most data regarding outcomes for this group of tumors are related to ganglioglioma and DNET since they are the most common tumors within the group. Seizure outcomes after surgical intervention are of particular interest since seizures are the most common presenting symptom of these tumors. Mehrotra et al reviewed seizure outcomes for a series of 26 patients with seizures related to neuronal/glioneuronal brain tumors.[63]
Favorable prognostic factors for postoperative improvement included earlier diagnosis, younger patient age, and focal partial seizure semiology. Early operative intervention was associated with the best long-term seizure outcomes. The extent of resection may also play an essential role in creating seizure freedom with surgery. A comprehensive review of the literature, including 1181 patients undergoing tumor resection with the intent of seizure control, demonstrated that 79% of patients who underwent a gross total tumor resection were seizure-free compared to only 43% of patients who underwent subtotal resection.[64]
Furthermore, patients with gross total resection plus resection of some surrounding tissue experienced 87% postoperative seizure freedom, which suggests that it may be important to respect surrounding dysplastic tissue during tumor resection. Similar findings have been demonstrated in children with epilepsy related to neuronal/glioneuronal brain tumors.[65] Significantly, shorter seizure duration is associated with improved cognitive outcomes in children, so prompt diagnosis and management in children with these brain tumors are of the utmost importance.
A specific outcome measure important for central neurocytoma is the need for long-term management of hydrocephalus with CSF shunting. The gross total resection of these tumors is related to lower ventricular shunting rates.[66]
Anaplastic ganglioglioma carries the worst prognosis of any tumor within this group. An analysis of available cases in the literature suggested a poor overall survival with the median at 29 months despite maximal therapy.[52]
Generating accurate prognoses for many of the other tumors in this group is somewhat difficult due to their rare nature. However, most appear relatively benign on histological and molecular characterization and are given low WHO grades, which suggests a favorable long-term survival. The main concern is the ability to control symptoms related to the tumors, often via surgical intervention, as discussed.
Complications
Complications related to neuronal and glioneuronal brain tumors are variable based on different treatment modalities. Adverse effects from anti-epileptic medications are common and include irritability, dizziness, drowsiness, blurred vision, difficulty with coordination, generalized fatigue, and weight gain.[67]
More serious side effects are also possible, including severe skin reactions and congenital disabilities in children if taken during pregnancy. Other complications are related to surgical intervention, including infection, intracranial and extracranial bleeding, postoperative hydrocephalus, new neurological deficit, lack of seizure control, injury to structures surrounding the tumor such as cranial nerves or blood vessels, cerebral edema and brain swelling, and death.
Consultations
Patients with a neuronal or glioneuronal brain tumor require interprofessional discussion. Patients with LEATs require consultation with neurosurgeons, epilepsy neurologists, neuroradiologists, and occasionally medical oncologists, radiation oncologists, and neuropathologists. These consultations often occur in the form of an interprofessional epilepsy conference. These and other patients with neuronal and glioneuronal brain tumors may also be discussed at an interprofessional tumor board conference, including neurosurgeons, neurologists, neuroradiologists, neuropathologists, radiation oncologists, and medical oncologists.
Deterrence and Patient Education
Patients with tumor-related epilepsy should be educated regarding seizure precautions and avoidance of secondary injury that may occur during a seizure. Family members should also be educated in recognizing seizure activity and the necessary actions to take when a seizure occurs. Patients with brain tumors should notify their provider of any new neurological symptoms, potentially representing changes to the tumor.
Enhancing Healthcare Team Outcomes
Neuronal and glioneuronal brain tumors are a heterogeneous group of tumors, so their presentations and management are variable. Therefore, effective evaluation and treatment require interprofessional input, which typically occurs in the form of epilepsy or tumor board conferences. Epilepsy evaluation requires the coordinated efforts of technicians, nurses, advanced practice providers, and physicians to appropriately identify seizure foci and ensure accurate and effective treatment for patients.
Emergency medical personnel must recognize acute neurological status changes to expedite emergency evaluation and medical or surgical responses, which helps minimize morbidity and mortality related to brain tumors. The inpatient care of postoperative brain tumor patients is complicated and requires the coordinated care of therapists, nurses, advanced practice providers, physicians, and other healthcare team members.
Specialty training regarding neurological evaluation is of utmost importance so that patient status changes are promptly recognized, and action can be taken. Therefore, increasing the awareness of these tumors among various healthcare providers helps facilitate early recognition and the effective care of these patients.
References
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-oncology. 2021 Aug 2:23(8):1231-1251. doi: 10.1093/neuonc/noab106. Epub [PubMed PMID: 34185076]
Shin JH, Lee HK, Khang SK, Kim DW, Jeong AK, Ahn KJ, Choi CG, Suh DC. Neuronal tumors of the central nervous system: radiologic findings and pathologic correlation. Radiographics : a review publication of the Radiological Society of North America, Inc. 2002 Sep-Oct:22(5):1177-89 [PubMed PMID: 12235346]
Level 2 (mid-level) evidenceGiulioni M, Rubboli G, Marucci G, Martinoni M, Marliani AF, Bartiromo F, Calbucci F. Focal epilepsies associated with glioneuronal tumors: review article. Panminerva medica. 2013 Jun:55(2):225-38 [PubMed PMID: 23676963]
Abdel Razek AAK,Elsebaie NA,Zamora C,Castillo M, Imaging of Neuronal and Mixed Glioneuronal Tumors. Journal of computer assisted tomography. 2020 May/Jun; [PubMed PMID: 32217897]
Srinivasa K, Cross KA, Dahiya S. BRAF Alteration in Central and Peripheral Nervous System Tumors. Frontiers in oncology. 2020:10():574974. doi: 10.3389/fonc.2020.574974. Epub 2020 Sep 15 [PubMed PMID: 33042847]
Debinski W, Krauze AV. Glioneuronal Tumors: Insights into a Rare Tumor Entity. Gliomas. 2021 Apr 30:(): [PubMed PMID: 34038055]
Choi E, Kim SI, Won JK, Chung CK, Kim SK, Choi SH, Choi S, Han B, Ahn B, Im SW, Park SH. Clinicopathological and molecular analysis of multinodular and vacuolating neuronal tumors of the cerebrum. Human pathology. 2019 Apr:86():203-212. doi: 10.1016/j.humpath.2018.11.028. Epub 2018 Dec 11 [PubMed PMID: 30550736]
Stone TJ, Keeley A, Virasami A, Harkness W, Tisdall M, Izquierdo Delgado E, Gutteridge A, Brooks T, Kristiansen M, Chalker J, Wilkhu L, Mifsud W, Apps J, Thom M, Hubank M, Forshew T, Cross JH, Hargrave D, Ham J, Jacques TS. Comprehensive molecular characterisation of epilepsy-associated glioneuronal tumours. Acta neuropathologica. 2018 Jan:135(1):115-129. doi: 10.1007/s00401-017-1773-z. Epub 2017 Oct 20 [PubMed PMID: 29058119]
Métais A, Appay R, Pagès M, Gallardo C, Silva K, Siegfried A, Perbet R, Maurage CA, Scavarda D, Fina F, Uro-Coste E, Riffaud L, Colin C, Figarella-Branger D, contributors of the Biopathology RENOCLIP-LOC network. Low-grade epilepsy-associated neuroepithelial tumours with a prominent oligodendroglioma-like component: The diagnostic challenges. Neuropathology and applied neurobiology. 2022 Feb:48(2):e12769. doi: 10.1111/nan.12769. Epub 2021 Nov 4 [PubMed PMID: 34551121]
Slegers RJ, Blumcke I. Low-grade developmental and epilepsy associated brain tumors: a critical update 2020. Acta neuropathologica communications. 2020 Mar 9:8(1):27. doi: 10.1186/s40478-020-00904-x. Epub 2020 Mar 9 [PubMed PMID: 32151273]
Bale TA. FGFR- gene family alterations in low-grade neuroepithelial tumors. Acta neuropathologica communications. 2020 Feb 21:8(1):21. doi: 10.1186/s40478-020-00898-6. Epub 2020 Feb 21 [PubMed PMID: 32085805]
Sekar A, Rudrappa S, Gopal S, Ghosal N, Rai A. Rosette-Forming Glioneuronal Tumor in Opticochiasmatic Region-Novel Entity in New Location. World neurosurgery. 2019 May:125():253-256. doi: 10.1016/j.wneu.2019.02.003. Epub 2019 Feb 18 [PubMed PMID: 30790744]
Zamora C, Castillo M. From Dysembryoplastic Neuroepithelial Tumors to Myxoid Glioneuronal Tumors, a New Entity. AJNR. American journal of neuroradiology. 2021 Nov:42(11):E77-E78. doi: 10.3174/ajnr.A7273. Epub 2021 Sep 16 [PubMed PMID: 34531194]
Lucas CG, Villanueva-Meyer JE, Whipple N, Oberheim Bush NA, Cooney T, Chang S, McDermott M, Berger M, Cham E, Sun PP, Putnam A, Zhou H, Bollo R, Cheshier S, Poppe MM, Fung KM, Sung S, Glenn C, Fan X, Bannykh S, Hu J, Danielpour M, Li R, Alva E, Johnston J, Van Ziffle J, Onodera C, Devine P, Grenert JP, Lee JC, Pekmezci M, Tihan T, Bollen AW, Perry A, Solomon DA. Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic features. Brain pathology (Zurich, Switzerland). 2020 May:30(3):479-494. doi: 10.1111/bpa.12797. Epub 2019 Nov 6 [PubMed PMID: 31609499]
Nagaishi M, Nobusawa S, Matsumura N, Kono F, Ishiuchi S, Abe T, Ebato M, Wang Y, Hyodo A, Yokoo H, Nakazato Y. SLC44A1-PRKCA fusion in papillary and rosette-forming glioneuronal tumors. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2016 Jan:23():73-75. doi: 10.1016/j.jocn.2015.04.021. Epub 2015 Aug 7 [PubMed PMID: 26260115]
Pages M, Lacroix L, Tauziede-Espariat A, Castel D, Daudigeos-Dubus E, Ridola V, Gilles S, Fina F, Andreiuolo F, Polivka M, Lechapt-Zalcman E, Puget S, Boddaert N, Liu XQ, Bridge JA, Grill J, Chretien F, Varlet P. Papillary glioneuronal tumors: histological and molecular characteristics and diagnostic value of SLC44A1-PRKCA fusion. Acta neuropathologica communications. 2015 Dec 15:3():85. doi: 10.1186/s40478-015-0264-5. Epub 2015 Dec 15 [PubMed PMID: 26671581]
Dragoo DD, Taher A, Wong VK, Elsaiey A, Consul N, Mahmoud HS, Mujtaba B, Stanietzky N, Elsayes KM. PTEN Hamartoma Tumor Syndrome/Cowden Syndrome: Genomics, Oncogenesis, and Imaging Review for Associated Lesions and Malignancy. Cancers. 2021 Jun 22:13(13):. doi: 10.3390/cancers13133120. Epub 2021 Jun 22 [PubMed PMID: 34206559]
Poyuran R, Mahadevan A, Mhatre R, Arimappamagan A, Sinha S, Bharath RD, Rao MB, Saini J, Raghavendra K, Mundlamuri RC, Sadashiva N, Rajeswaran J, Satishchandra P, Chandramouli BA, Shankar SK. Neuropathological spectrum of drug resistant epilepsy: 15-years-experience from a tertiary care centre. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2021 Sep:91():226-236. doi: 10.1016/j.jocn.2021.07.014. Epub 2021 Jul 20 [PubMed PMID: 34373032]
Giulioni M, Marucci G, Martinoni M, Marliani AF, Toni F, Bartiromo F, Volpi L, Riguzzi P, Bisulli F, Naldi I, Michelucci R, Baruzzi A, Tinuper P, Rubboli G. Epilepsy associated tumors: Review article. World journal of clinical cases. 2014 Nov 16:2(11):623-41. doi: 10.12998/wjcc.v2.i11.623. Epub [PubMed PMID: 25405186]
Level 3 (low-level) evidenceBlümcke I, Thom M, Aronica E, Armstrong DD, Vinters HV, Palmini A, Jacques TS, Avanzini G, Barkovich AJ, Battaglia G, Becker A, Cepeda C, Cendes F, Colombo N, Crino P, Cross JH, Delalande O, Dubeau F, Duncan J, Guerrini R, Kahane P, Mathern G, Najm I, Ozkara C, Raybaud C, Represa A, Roper SN, Salamon N, Schulze-Bonhage A, Tassi L, Vezzani A, Spreafico R. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia. 2011 Jan:52(1):158-74. doi: 10.1111/j.1528-1167.2010.02777.x. Epub 2010 Nov 10 [PubMed PMID: 21219302]
Level 3 (low-level) evidenceBarba C, Coras R, Giordano F, Buccoliero AM, Genitori L, Blümcke I, Guerrini R. Intrinsic epileptogenicity of gangliogliomas may be independent from co-occurring focal cortical dysplasia. Epilepsy research. 2011 Nov:97(1-2):208-13. doi: 10.1016/j.eplepsyres.2011.07.004. Epub 2011 Aug 9 [PubMed PMID: 21831599]
Level 3 (low-level) evidenceChassoux F, Landré E, Mellerio C, Laschet J, Devaux B, Daumas-Duport C. Dysembryoplastic neuroepithelial tumors: epileptogenicity related to histologic subtypes. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2013 Jun:124(6):1068-78. doi: 10.1016/j.clinph.2012.11.015. Epub 2012 Dec 29 [PubMed PMID: 23276492]
Level 2 (mid-level) evidenceWolf HK, Birkholz T, Wellmer J, Blümcke I, Pietsch T, Wiestler OD. Neurochemical profile of glioneuronal lesions from patients with pharmacoresistant focal epilepsies. Journal of neuropathology and experimental neurology. 1995 Sep:54(5):689-97 [PubMed PMID: 7666058]
Level 2 (mid-level) evidenceAronica E, Yankaya B, Jansen GH, Leenstra S, van Veelen CW, Gorter JA, Troost D. Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumours from patients with intractable epilepsy. Neuropathology and applied neurobiology. 2001 Jun:27(3):223-37 [PubMed PMID: 11489142]
Fassunke J, Majores M, Tresch A, Niehusmann P, Grote A, Schoch S, Becker AJ. Array analysis of epilepsy-associated gangliogliomas reveals expression patterns related to aberrant development of neuronal precursors. Brain : a journal of neurology. 2008 Nov:131(Pt 11):3034-50. doi: 10.1093/brain/awn233. Epub 2008 Sep 26 [PubMed PMID: 18819986]
Samadani U, Judkins AR, Akpalu A, Aronica E, Crino PB. Differential cellular gene expression in ganglioglioma. Epilepsia. 2007 Apr:48(4):646-53 [PubMed PMID: 17437409]
Cheng CH,Liu CL,Chen CC,Lin SZ,Cho DY, Single-port endoscopic removal of intraventricular central neurocytoma. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2010 Nov; [PubMed PMID: 20655233]
Level 3 (low-level) evidenceSmith TW, Nikulasson S, De Girolami U, De Gennaro LJ. Immunohistochemistry of synapsin I and synaptophysin in human nervous system and neuroendocrine tumors. Applications in diagnostic neuro-oncology. Clinical neuropathology. 1993 Nov-Dec:12(6):335-42 [PubMed PMID: 8287627]
Isgrò MA, Bottoni P, Scatena R. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects. Advances in experimental medicine and biology. 2015:867():125-43. doi: 10.1007/978-94-017-7215-0_9. Epub [PubMed PMID: 26530364]
Level 3 (low-level) evidencePuzyrenko A, Cochran E, Giorgadze T, Nomani L. Papillary glioneuronal tumors: Distinctive cytological characteristics and cyto-histologic correlation. Annals of diagnostic pathology. 2021 Aug:53():151757. doi: 10.1016/j.anndiagpath.2021.151757. Epub 2021 May 10 [PubMed PMID: 33991783]
Abongwa C, Cotter J, Tamrazi B, Dhall G, Davidson T, Margol A. Primary diffuse leptomeningeal glioneuronal tumors of the central nervous system: Report of three cases and review of literature. Pediatric hematology and oncology. 2020 Apr:37(3):248-258. doi: 10.1080/08880018.2019.1711270. Epub 2020 Jan 17 [PubMed PMID: 31951480]
Level 3 (low-level) evidenceVerbančič T, Ravnik J, Kavalar R. Rosette-forming glioneuronal tumor of the fourth ventricle; A case report and review of the literature. Clinical case reports. 2021 Jun:9(6):e04355. doi: 10.1002/ccr3.4355. Epub 2021 Aug 17 [PubMed PMID: 34429970]
Level 3 (low-level) evidenceSáez-Alegre M, Saceda Gutiérrez JM, Utrilla Contreras C, Aracil Santos FJ, García-Feijoo P, Carceller Benito F. Diffuse leptomeningeal glioneuronal tumour: where to biopsy? Case report and literature review. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. 2021 Jul:37(7):2405-2408. doi: 10.1007/s00381-020-04955-2. Epub 2020 Oct 31 [PubMed PMID: 33128604]
Level 3 (low-level) evidenceZhang D, Wen L, Henning TD, Feng XY, Zhang YL, Zou LG, Zhang ZG. Central neurocytoma: clinical, pathological and neuroradiological findings. Clinical radiology. 2006 Apr:61(4):348-57 [PubMed PMID: 16546465]
Level 3 (low-level) evidenceRamsahye H, He H, Feng X, Li S, Xiong J. Central neurocytoma: radiological and clinico-pathological findings in 18 patients and one additional MRS case. Journal of neuroradiology = Journal de neuroradiologie. 2013 May:40(2):101-11. doi: 10.1016/j.neurad.2012.05.007. Epub 2013 Feb 12 [PubMed PMID: 23410895]
Level 3 (low-level) evidenceLuzzi S, Elia A, Del Maestro M, Elbabaa SK, Carnevale S, Guerrini F, Caulo M, Morbini P, Galzio R. Dysembryoplastic Neuroepithelial Tumors: What You Need to Know. World neurosurgery. 2019 Jul:127():255-265. doi: 10.1016/j.wneu.2019.04.056. Epub 2019 Apr 11 [PubMed PMID: 30981794]
Joo G, Doumanian J. Radiographic Findings of Dysplastic Cerebellar Gangliocytoma (Lhermitte-Duclos Disease) in a Woman with Cowden Syndrome: A Case Study and Literature Review. Journal of radiology case reports. 2020 Mar:14(3):1-6. doi: 10.3941/jrcr.v14i3.3814. Epub 2020 Mar 31 [PubMed PMID: 33082915]
Level 3 (low-level) evidenceThomas B, Krishnamoorthy T, Radhakrishnan VV, Kesavadas C. Advanced MR imaging in Lhermitte-Duclos disease: moving closer to pathology and pathophysiology. Neuroradiology. 2007 Sep:49(9):733-8 [PubMed PMID: 17549467]
Level 3 (low-level) evidenceGaballo A,Palma M,Dicuonzo F,Carella A, Lhermitte-Duclos disease: MR diffusion and spectroscopy. La Radiologia medica. 2005 Oct; [PubMed PMID: 16292245]
Level 3 (low-level) evidenceSchramm J, Aliashkevich AF. Surgery for temporal mediobasal tumors: experience based on a series of 235 patients. Neurosurgery. 2008 Jun:62(6 Suppl 3):1272-82. doi: 10.1227/01.neu.0000333792.36715.29. Epub [PubMed PMID: 18695547]
Vivas AC, Reintjes S, Shimony N, Vale FL. Surgery of the amygdala and uncus: a case series of glioneuronal tumors. Acta neurochirurgica. 2020 Apr:162(4):795-801. doi: 10.1007/s00701-020-04249-1. Epub 2020 Jan 30 [PubMed PMID: 31997072]
Level 2 (mid-level) evidenceIshikawa T, Muragaki Y, Maruyama T, Abe K, Kawamata T. Roles of the Wada Test and Functional Magnetic Resonance Imaging in Identifying the Language-dominant Hemisphere among Patients with Gliomas Located near Speech Areas. Neurologia medico-chirurgica. 2017 Jan 15:57(1):28-34. doi: 10.2176/nmc.oa.2016-0042. Epub 2016 Dec 15 [PubMed PMID: 27980284]
Zaghloul KA,Schramm J, Surgical management of glioneuronal tumors with drug-resistant epilepsy. Acta neurochirurgica. 2011 Aug; [PubMed PMID: 21603887]
Klimko A, Dandes M, Paslaru F, Giovani A. Primary Anaplastic Ganglioglioma of the Temporal Lobe With Brainstem Involvement: A Case Report and Literature Review. Cureus. 2020 Dec 13:12(12):e12060. doi: 10.7759/cureus.12060. Epub 2020 Dec 13 [PubMed PMID: 33447489]
Level 3 (low-level) evidenceHaydon DH, Dahiya S, Smyth MD, Limbrick DD, Leonard JR. Greater extent of resection improves ganglioglioma recurrence-free survival in children: a volumetric analysis. Neurosurgery. 2014 Jul:75(1):37-42. doi: 10.1227/NEU.0000000000000349. Epub [PubMed PMID: 24625425]
Level 2 (mid-level) evidenceVasiljevic A, François P, Loundou A, Fèvre-Montange M, Jouvet A, Roche PH, Figarella-Branger D. Prognostic factors in central neurocytomas: a multicenter study of 71 cases. The American journal of surgical pathology. 2012 Feb:36(2):220-7. doi: 10.1097/PAS.0b013e31823b8232. Epub [PubMed PMID: 22251941]
Level 2 (mid-level) evidenceGoel A,Vutha R,Shah A,Singh K,Goel N,Shenoy A,Rai S,Dandpat S, Large lateral intraventricular tumors - Outcome of radical surgery. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2021 Jun; [PubMed PMID: 33992185]
Okasha M, Ineson G, Pesic-Smith J, Surash S. Transcortical Approach to Deep-Seated Intraventricular and Intra-axial Tumors Using a Tubular Retractor System: A Technical Note and Review of the Literature. Journal of neurological surgery. Part A, Central European neurosurgery. 2021 May:82(3):270-277. doi: 10.1055/s-0040-1719025. Epub 2020 Dec 15 [PubMed PMID: 33321519]
Salem U, Kumar VA, Madewell JE, Schomer DF, de Almeida Bastos DC, Zinn PO, Weinberg JS, Rao G, Prabhu SS, Colen RR. Neurosurgical applications of MRI guided laser interstitial thermal therapy (LITT). Cancer imaging : the official publication of the International Cancer Imaging Society. 2019 Oct 15:19(1):65. doi: 10.1186/s40644-019-0250-4. Epub 2019 Oct 15 [PubMed PMID: 31615562]
Selvanathan SK, Hammouche S, Salminen HJ, Jenkinson MD. Outcome and prognostic features in anaplastic ganglioglioma: analysis of cases from the SEER database. Journal of neuro-oncology. 2011 Dec:105(3):539-45. doi: 10.1007/s11060-011-0615-4. Epub 2011 May 29 [PubMed PMID: 21626070]
Level 3 (low-level) evidenceTerrier LM,Bauchet L,Rigau V,Amelot A,Zouaoui S,Filipiak I,Caille A,Almairac F,Aubriot-Lorton MH,Bergemer-Fouquet AM,Bord E,Cornu P,Czorny A,Dam Hieu P,Debono B,Delisle MB,Emery E,Farah W,Gauchotte G,Godfraind C,Guyotat J,Irthum B,Janot K,Le Reste PJ,Liguoro D,Loiseau H,Lot G,Lubrano V,Mandonnet E,Menei P,Metellus P,Milin S,Muckenstrum B,Roche PH,Rousseau A,Uro-Coste E,Vital A,Voirin J,Wager M,Zanello M,François P,Velut S,Varlet P,Figarella-Branger D,Pallud J,Zemmoura I,Club de Neuro-Oncologie of the Société Française de Neurochirurgie., Natural course and prognosis of anaplastic gangliogliomas: a multicenter retrospective study of 43 cases from the French Brain Tumor Database. Neuro-oncology. 2017 May 1; [PubMed PMID: 28453747]
Level 2 (mid-level) evidenceMallick S, Benson R, Melgandi W, Giridhar P, Rath GK. Impact of surgery, adjuvant treatment, and other prognostic factors in the management of anaplastic ganglioglioma. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. 2018 Jun:34(6):1207-1213. doi: 10.1007/s00381-018-3780-3. Epub 2018 Mar 29 [PubMed PMID: 29594461]
Samhouri L, Meheissen MAM, Ibrahimi AKH, Al-Mousa A, Zeineddin M, Elkerm Y, Hassanein ZMA, Ismail AA, Elmansy H, Al-Hanaqta MM, Al-Azzam OA, Elsaid AA, Kittel C, Micke O, Stummer W, Elsayad K, Eich HT. Impact of Adjuvant Radiotherapy in Patients with Central Neurocytoma: A Multicentric International Analysis. Cancers. 2021 Aug 26:13(17):. doi: 10.3390/cancers13174308. Epub 2021 Aug 26 [PubMed PMID: 34503124]
Mallick S, Benson R, Rath GK. Patterns of care and survival outcomes in patients with an extraventricular neurocytoma: An individual patient data analysis of 201 cases. Neurology India. 2018 Mar-Apr:66(2):362-367. doi: 10.4103/0028-3886.227262. Epub [PubMed PMID: 29547155]
Level 3 (low-level) evidenceChen YD,Li WB,Feng J,Qiu XG, Long-term outcomes of adjuvant radiotherapy after surgical resection of central neurocytoma. Radiation oncology (London, England). 2014 Nov 6; [PubMed PMID: 25373333]
Level 2 (mid-level) evidenceGembruch O, Junker A, Mönninghoff C, Ahmadipour Y, Darkwah Oppong M, Sure U, El Hindy N, Lemonas E. Liponeurocytoma: Systematic Review of a Rare Entity. World neurosurgery. 2018 Dec:120():214-233. doi: 10.1016/j.wneu.2018.09.001. Epub 2018 Sep 8 [PubMed PMID: 30205225]
Level 1 (high-level) evidenceWang KE, Ni M, Wang L, Jia G, Wu Z, Zhang L, Zhang J. Cerebellar liponeurocytoma: A case report and review of the literature. Oncology letters. 2016 Feb:11(2):1061-1064 [PubMed PMID: 26893691]
Level 3 (low-level) evidenceAl-Umran MR, Al-Umran SR, Arab AF, Dababo MA, Alotaibi FA. Lateral ventricular liponeurocytoma: Review of literature and case illustration. Neuro-Chirurgie. 2021 Nov:67(6):579-586. doi: 10.1016/j.neuchi.2021.03.004. Epub 2021 Mar 22 [PubMed PMID: 33766564]
Level 3 (low-level) evidenceMarks AM,Bindra RS,DiLuna ML,Huttner A,Jairam V,Kahle KT,Kieran MW, Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib. Pediatric blood [PubMed PMID: 29380516]
Kowalewski A, Durślewicz J, Zdrenka M, Grzanka D, Szylberg Ł. Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm. Targeted oncology. 2020 Aug:15(4):531-540. doi: 10.1007/s11523-020-00735-9. Epub [PubMed PMID: 32648041]
Johnson MO, Kirkpatrick JP, Patel MP, Desjardins A, Randazzo DM, Friedman HS, Ashley DM, Peters KB. The role of chemotherapy in the treatment of central neurocytoma. CNS oncology. 2019 Nov 1:8(3):CNS41. doi: 10.2217/cns-2019-0012. Epub 2019 Nov 5 [PubMed PMID: 31686534]
Buchbinder D, Danielpour M, Yong WH, Salamon N, Lasky J. Treatment of atypical central neurocytoma in a child with high dose chemotherapy and autologous stem cell rescue. Journal of neuro-oncology. 2010 May:97(3):429-37. doi: 10.1007/s11060-009-0029-8. Epub 2009 Nov 19 [PubMed PMID: 19924515]
Level 3 (low-level) evidenceMehrotra A,Singh S,Kanjilal S,Pal L,Paliwal VK,Sardhara J,Behari S, Seizure-outcome after surgery of low-grade epilepsy associated neuro-epithelial tumors. Journal of neurosurgical sciences. 2020 Dec 15; [PubMed PMID: 33320468]
Englot DJ, Han SJ, Berger MS, Barbaro NM, Chang EF. Extent of surgical resection predicts seizure freedom in low-grade temporal lobe brain tumors. Neurosurgery. 2012 Apr:70(4):921-8; discussion 928. doi: 10.1227/NEU.0b013e31823c3a30. Epub [PubMed PMID: 21997540]
Level 1 (high-level) evidenceFaramand AM, Barnes N, Harrison S, Gunny R, Jacques T, Tahir MZ, Varadkar SM, Cross HJ, Harkness W, Tisdall MM. Seizure and cognitive outcomes after resection of glioneuronal tumors in children. Epilepsia. 2018 Jan:59(1):170-178. doi: 10.1111/epi.13961. Epub 2017 Nov 26 [PubMed PMID: 29178251]
Soliman WS. Ventricular Central Neurocytoma: Rate of Shunting and Outcome 2 Years After Total and Subtotal Excision. Acta neurochirurgica. Supplement. 2017:124():179-185. doi: 10.1007/978-3-319-39546-3_28. Epub [PubMed PMID: 28120072]
Perucca P,Gilliam FG, Adverse effects of antiepileptic drugs. The Lancet. Neurology. 2012 Sep; [PubMed PMID: 22832500]